Advertisement
Canada markets close in 1 minute

  • S&P/TSX

    22,261.72
    +314.31 (+1.43%)
     

  • S&P 500

    5,179.26
    +51.47 (+1.00%)
     

  • DOW

    38,841.74
    +166.06 (+0.43%)
     

  • CAD/USD

    0.7317
    +0.0009 (+0.12%)
     

  • CRUDE OIL

    78.57
    +0.46 (+0.59%)
     

  • Bitcoin CAD

    86,395.55
    -926.81 (-1.06%)
     

  • CMC Crypto 200

    1,358.73
    +46.10 (+3.52%)
     

  • GOLD FUTURES

    2,332.70
    +24.10 (+1.04%)
     

  • RUSSELL 2000

    2,059.29
    +23.56 (+1.16%)
     

  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     

  • NASDAQ

    16,344.25
    +187.92 (+1.16%)
     

  • VOLATILITY

    13.53
    +0.04 (+0.30%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

  • CAD/EUR

    0.6793
    +0.0006 (+0.09%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS RALLY CONTINUES ON FED HOPES

Current rates should be enough to bring inflation down: Fed's Barkin

Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2 min read

For the quarter ended March 2024, Labcorp (LH) reported revenue of $3.18 billion, down 15.9% over the same period last year. EPS came in at $3.68, compared to $3.82 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $3.13 billion, representing a surprise of +1.59%. The company delivered an EPS surprise of +6.36%, with the consensus EPS estimate being $3.46.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Labcorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Biopharma Laboratory Services: $710.90 million versus $697.35 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -49.3% change.

  • Revenues- Diagnostics Laboratories: $2.48 billion compared to the $2.42 billion average estimate based on three analysts. The reported number represents a change of +4.1% year over year.

  • Adjusted Operating Income- Biopharma Laboratory Services: $99.90 million compared to the $92.47 million average estimate based on three analysts.

  • Adjusted Operating Income- Diagnostics Laboratories: $417.90 million versus $427.90 million estimated by three analysts on average.

View all Key Company Metrics for Labcorp here>>>

Shares of Labcorp have returned -4% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Labcorp (LH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research